1. Home
  2. MPB vs MLYS Comparison

MPB vs MLYS Comparison

Compare MPB & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mid Penn Bancorp

MPB

Mid Penn Bancorp

HOLD

Current Price

$36.99

Market Cap

827.5M

Sector

Finance

ML Signal

HOLD

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$28.31

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MPB
MLYS
Founded
1868
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
827.5M
2.5B
IPO Year
1996
2023

Fundamental Metrics

Financial Performance
Metric
MPB
MLYS
Price
$36.99
$28.31
Analyst Decision
Buy
Strong Buy
Analyst Count
1
7
Target Price
$37.00
$48.67
AVG Volume (30 Days)
72.7K
1.1M
Earning Date
04-21-2026
05-06-2026
Dividend Yield
2.66%
N/A
EPS Growth
N/A
37.43
EPS
1.22
N/A
Revenue
N/A
N/A
Revenue This Year
$30.95
N/A
Revenue Next Year
$9.45
N/A
P/E Ratio
$30.20
N/A
Revenue Growth
N/A
N/A
52 Week Low
$26.56
$22.30
52 Week High
$39.15
$47.65

Technical Indicators

Market Signals
Indicator
MPB
MLYS
Relative Strength Index (RSI) 48.29 52.31
Support Level $36.78 $25.56
Resistance Level $37.37 $31.36
Average True Range (ATR) 0.75 1.66
MACD -0.03 -0.07
Stochastic Oscillator 55.74 45.22

Price Performance

Historical Comparison
MPB
MLYS

About MPB Mid Penn Bancorp

Mid Penn Bancorp Inc is a financial holding company, providing various banking and financial products and services through its subsidiaries. These products and services mainly include consumer banking products, including secure checking and savings accounts, mobile banking, agricultural loans, construction financing, mortgages, home equity loans and lines of credit, credit cards, and more. Additionally, the Group offers trust services, insurance products, wealth management, and private banking services. The Group caters to individuals, partnerships, non-profit organizations, and corporations through its retail banking offices located throughout Pennsylvania, with a minor portion in New Jersey.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Share on Social Networks: